Patient outcomes and organizational impact of a valve-less trocar insufflation system in laparoscopic surgery: an update of a systematic review.

Systematic review / meta-analysis OA: gold CC-BY-NC-ND-4.0
⚙ AI-generated summary by qwen3.7-flash, 2026-11-13 ⓘ

This updated systematic review of 2,804 patients indicates that valve-less trocar insufflation systems reduce postoperative pain and analgesic consumption without affecting operative duration or complication rates compared to conventional insufflators.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-11-13 · read from full text ⓘ

This systematic review update evaluates the clinical and organizational impact of the AIRSEAL valve-less trocar insufflation system compared to standard CO2 insufflators across 21 studies involving 2,804 patients undergoing various laparoscopic procedures. The analysis focused on patient outcomes such as blood loss, pain, and complications, alongside operational metrics like operative time and hospital stay, but found that statistical pooling was inappropriate due to significant heterogeneity in reported results. Consequently, the authors provided a narrative synthesis rather than a meta-analysis, noting that while the technology offers technical advantages like stable pressure and smoke evacuation, definitive conclusions on its superiority over conventional systems remain inconclusive based on current evidence. Relevance to endometriosis: one included study by Madueke-Laveaux et al. specifically examined patients with endometriosis undergoing laparoscopic surgery, allowing for subgroup assessment of this device's utility in that context.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BackgroundA valve-less trocar insufflation system was developed to optimize pneumoperitoneum management during laparoscopic surgery. We updated a systematic review (SR) published in 2020 to evaluate the patient outcomes and organizational impact associated with the use of this system for low-pressure pneumoperitoneum in laparoscopic surgery.MethodsA structured search strategy was employed across multiple electronic databases to identify comparative studies published between April 2020 and June 2025, completing our previous search (January 2010 - April 2020). We were interested in population of patients with various medical conditions who underwent laparoscopic procedures using either the valve-less trocar insufflation system (AIRSEAL® device) or a conventional carbon dioxide insufflator.ResultsA total of 21 studies (10 from the previous SR /11 from the updated SR), of which 10 were randomized controlled trials and 11 were non- randomized controlled trials, were selected and enrolled 2,804 patients. Among the 10 studies that evaluated postoperative pain, five reported a significant reduction in shoulder pain and three showed a decrease in general pain- at 24-hour. For analgesic consumption, three out of five studies reported a significant decrease. Of the 18 studies that examined operative duration, 13 did not find a reduction when using AIRSEAL® device. Length of stay was similar across groups. The overall complication rates were comparable between the two insufflators. None of the studies performed a cost-effectiveness or health economic analysis.ConclusionThe systematic review synthesizes the current literature valve-less trocar insufflation systems and largely confirms their feasibility based on patient outcomes, although cost-effectiveness analysis on this system should be encouraged. This work may serve as a valuable basis for future evidence appraisal and the development of clinical practice guidelines.Trial registrationThe review protocol of the original systematic review was registered in PROSPERO (CRD42019145665).
Full text 40,915 characters · extracted from pmc-nxml · 6 sections · click to expand

Methods

This work is an update of a previous SR [ 3 ], which was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines [ 4 ]. The review protocol of the original SR was registered in PROSPERO (CRD42019145665). This review included comparative clinical studies, randomized or non-randomized (with either prospective or retrospective data collection), across all publication formats, except letters, editorials, commentaries, and conference abstracts. Studies were eligible if they complied with the following PICO criteria: a)- Population: patients of any age undergoing any form of laparoscopic surgery; b)- Intervention: use of a valve-less trocar insufflation system (AIRSEAL system [ConMed; Utica, New York, USA]) We focused on AIRSEAL, as it is the most extensively studied system, and we excluded other systems to ensure comparability between studies.; c)-Comparator: use of a standard CO 2 insufflator; unlike the previously published study protocol, we excluded studies that had surgery under laparotomy as comparative group in order to evaluate the actual impact of the AIRSEAL system; d)- Outcomes: we focused on two main categories: 1- clinical effectiveness and safety outcomes (patient outcomes) , including: rate of conversion from laparoscopy to laparotomy due to complications; volume of intraoperative blood loss and percentage of patients requiring blood transfusion before hospital discharge; severity of postoperative pain and analgesic consumption; incidence of severe postoperative complications (defined as grade II or higher according to Clavien–Dindo classification [ 5 ]); hospital readmission rate within 30 days to the procedure; 2- health economic and organizational outcomes , including: total operative time; time spent in the postoperative recovery area; length of hospital stay; costs associated with surgical management. Overall, these endpoints were selected on the basis that they represent the most clinically meaningful and objectively measurable outcomes attributable to the intraoperative performance of the AIRSEAL system. A systematic review of the literature was conducted in June 2024 across several major electronic databases, including PubMed/Medline (U.S. National Library of Medicine), Web of Science (Clarivate), Embase (Elsevier), Cochrane Library (Wiley), and Scopus (Elsevier), to identify relevant studies published from April 2020 to June 2024 (see Appendix 1 for full search details), completing the search over the period January 2010-April 2020 from the original SR. The search strategy combined controlled vocabulary terms (e.g., MeSH terms) and free-text keywords corresponding to the key concepts of the review topic. The search queries were developed by a trained information specialist (C.G.). To capture newly published studies, an automated search alert was maintained for all databases until June 2025. Grey literature was also explored by analyzing references identified through Google searches using precise thematic queries. Additional searches were conducted in ClinicalTrials.gov and PROSPERO to identify ongoing or unpublished studies, thereby strengthening methodological robustness. Screening of all retrieved records was performed independently by four reviewers using Covidence (covidence.org, Australia), first at the title and abstract level, followed by full-text assessment. Any disagreements were resolved through discussion until consensus was reached. The study selection process, along with the reasons for full-text exclusions, was documented in a PRISMA flow diagram (Fig.  1 ). Fig. 1 PRISMA flow chart of the new selection (update of the previous SR). PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA flow chart of the new selection (update of the previous SR). PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses Data extraction was performed by two pairs of reviewers utilizing a predefined and pre-tested extraction form, and all completed forms were subsequently cross-checked. Beyond the predefined outcomes, additional data on patient baseline characteristics and surgical procedures were also collected. Quality assessment was carried out independently by two pairs of reviewers, who cross-validated their evaluations. Discrepancies were resolved through discussion until consensus was achieved. The methodological quality of included studies was appraised using the checklist developed by the US National Institutes of Health for Controlled Intervention Studies [ 6 ]. Studies were classified as poor, fair, or good quality based on their limitations across the 14 checklist items. A narrative synthesis of study, population, and outcome characteristics was provided, complemented by summary tables. Due to the considerable heterogeneity in reported outcomes, statistical pooling under the form of meta-analysis was deemed inappropriate.

Results

A total of 824 records were initially identified and screened at title/abstract level. Of these, 104 full-text articles were assessed for eligibility, of which 11 studies [ 7 – 17 ] were included and added to the 10 studies [ 1 , 2 , 18 – 25 ] from the previous SR [ 3 ]. Overall, 21 studies, gathering 2,804 patients in total, matched our eligibility criteria (see Fig. 1 ). Table 1 Description of the included studies and patients by specialties Year Country Authors PMID Specialty Oncology Design Type of procedures Patient number AIRSEAL ® vs. Control Age (year) AIRSEAL ® vs. Control Female (%) AIRSEAL ® vs. Control BMI (kg/m²) AIRSEAL ® vs. Control 2011 USA Herati et al. [ 25 ] 20,888,033 Urology Yes PNRCT Renal surgery 26 vs. 25 61.6 ± 14.2 vs. 59.7 ± 14.3 46.2 vs. 40 30.8 ± 6.3 vs. 29.3 ± 7.3 2013 Switzerland Horstmann et al. [ 2 ] 23,186,377 Urology Yes PNRCT Radical Prostatectomy 19 vs. 17 64 vs.65 0 vs. 0 28 vs. 26 2015 USA George et al. [ 26 ] 25,725,807 Urology Yes Retro Prostatectomy 257 vs. 385 62.3 (32.1–76.6) vs. 62.6 (42.7–75.4) 0 vs.0 27.6 (16.2–47.4) vs. 27.3 (17.8–41.4) 2016 USA Bucur et al. [ 1 ] 27,130,263 Urology Yes RCT Renal surgery 28 vs. 28 62.5 (15.3) vs. 64.8 (13.1) 17.9 vs. 35.7 27.9 (6.2) vs. 28.7 (4.1) 2017 Italy Annino et al. [ 22 ] 27,495,337 Urology Yes PNRCT Partial nephrectomy 67 vs. 55 66.3 vs. 67.1 29.9 vs. 25.5 na vs. na 2017 Italy Covotta et al. [ 21 ] 28,452,822 Urology Yes RCT Cystectomy 28 vs. 28 60.2 (6.5) vs. 61.1 (9.1) 28.6 vs. 28.6 25.9 (3.5) vs. 26.5 (3.9) 2019 USA Shahait et al. [ 19 ] 30,740,014 Urology Yes PNRCT Radical Prostatectomy 100 vs. 100 62 ± 7 vs. 62 ± 7 0 vs. 0 28.5 ± 4.2 vs. 27.2 ± 4.5 2021 USA Feng et al. [ 8 ] 32,632,561 Urology Yes RCT Partial nephrectomy 31 vs. 31 31 60.1 (11) vs. 61.0 (11.6) / 60.4 (12) 39 vs. 39 / 42 30.0 (5.2) vs. 28.7 (5.7) / 31.0 (5.31) 2021 USA Abaza et al. [ 9 ] 33,349,135 Urology Yes RCT Prostatectomy 50 vs. 50 61 ± 5.6 vs. 62 ± 6.7 0 vs. 0 29.1 ± 4.3 vs. 28.3 ± 3.3 2021 USA Desroches et al. [ 10 ] 33,577,899 Urology Na RCT Partial nephrectomy 66 vs. 66 69 60.1 (13.3) vs. 60 (12.5) / 60.1 (11.8) 35 vs. 35 / 38 29.2 (6.0) vs. 28.9 (5.6) / 31.2 (5.6) 2023 Lebanon Ayoub et al. [ 14 ] 37,704,868 Urology Yes Retro Radical Prostatectomy 125 vs. 201 65.1 ± 6.6 vs. 63.7 ± 7.3 0 vs. 0 28.8 ± 4.2 vs. 28.4 ± 5 2023 Italy Forte et al. [ 15 ] 37,440,928 Urology Yes Retro Partial nephrectomy 14 vs. 13 61.3 vs. 65.9 21.4 vs. 30.7 na vs. na 2024 China Wei et al. [ 17 ] 38,381,369 Urology Yes RCT Partial nephrectomy 31 vs. 31 53 (48; 64) vs. 57 (44; 63) 35.5 vs. 45.2 25.4 (22.7–27.7) vs. 24.3 (22.6–27.0) 2024 USA Chien et al. [ 16 ] 37,819,689 Urology No Retro Pyeloplasty 14 vs. 12 8.8 (3.7–15.6) vs. 8.9 (4.6–17.6) 28.6 vs. 41.7 17.3 (16.4–22.3) vs. 16.5 (15.0–19.1) 2016 Japan Miyano et al. [ 23 ] 28,029,370 Abdominal No PNRCT Appendectomy 18 vs. 21 7.4 vs. 8.1 na vs. na na vs. na 2021 USA Paull et al. [ 7 ] 32,333,365 Abdominal Yes Retro LAR Right hemicolectomy 40 vs. 54 24 vs. 32 55.2 ± 15.4 vs. 58.4 ± 9.7 55.5 ± 18.2 vs. 64.2 ± 13.2 55.0 vs. 42.6 70.8 vs. 46.9 27.9 ± 7.8 vs. 28.4 ± 6.5 29.7 ± 7.5 vs. 29.1 ± 7.3 2021 Austria Luketina et al. [ 11 ] 32,767,145 Abdominal No RCT Cholecystectomy Sigmoid resection 96 vs. 97 54.0 ± 12.9 vs. 55.2 ± 13.2 54.2 vs. 54.6 27.4 (24.6–31.0) vs. 27.8 (24.8–30.1) 2017 France Sroussi et al. [ 20 ] 28,403,972 Gynecology No RCT Tubal patency test Salpingectomy 30 vs. 30 33 (19–45) vs. 35 (25–58) 30 vs. 30 22.1 (19-29.4) vs. 22.6 (19.3–31.2) 2020 USA Madueke-Laveaux et al. [ 18 ] 31,125,720 Gynecology No RCT Uterine myomas Endometriosis 33 vs.33 33 vs.33 40 ± 9 vs. 40 ± 7 39 ± 7 vs. 36 ± 8 100 vs. 100 27 ± 6 vs. 28 28 ± 7 vs. 27 2022 France Delecourt et al. [ 13 ] 35,569,811 Gynecology No RCT Hysterectomy for benign condition 40 vs. 40 48.5 (7) vs. 46.5 (6) 100 vs. 100 25.3 (9.3) vs. 25.5 (5.5) 2022 Italy Buda et al. [ 12 ] 35,327,010 Gynecology Yes Retro Early-stage endometrial cancer 84 vs. 68 63 (52–73) vs. 65 (54–75) 100 30.0 (23.7–36.4) vs. 27.9 (22.6–33.2) Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range) LAR low anterior resection, PNRCT prospective non randomized clinical trials, Retro Retrospective, RCT Randomized Clinical Trials, na no data available Description of the included studies and patients by specialties 2011 USA Herati et al. [ 25 ] 20,888,033 Urology Yes PNRCT 61.6 ± 14.2 vs. 59.7 ± 14.3 2013 Switzerland Horstmann et al. [ 2 ] 23,186,377 Urology Yes PNRCT 2015 USA George et al. [ 26 ] 25,725,807 Urology Yes Retro 27.6 (16.2–47.4) vs. 27.3 (17.8–41.4) 2016 USA Bucur et al. [ 1 ] 27,130,263 Urology Yes RCT 62.5 (15.3) vs. 64.8 (13.1) 27.9 (6.2) vs. 28.7 (4.1) 2017 Italy Annino et al. [ 22 ] 27,495,337 Urology Yes PNRCT 2017 Italy Covotta et al. [ 21 ] 28,452,822 Urology Yes RCT 60.2 (6.5) vs. 61.1 (9.1) 25.9 (3.5) vs. 26.5 (3.9) 2019 USA Shahait et al. [ 19 ] 30,740,014 Urology Yes PNRCT 2021 USA Feng et al. [ 8 ] 32,632,561 Urology Yes RCT 31 vs. 31 31 60.1 (11) vs. 61.0 (11.6) / 60.4 (12) 39 vs. 39 / 42 30.0 (5.2) vs. 28.7 (5.7) / 31.0 (5.31) 2021 USA Abaza et al. [ 9 ] 33,349,135 Urology Yes RCT 61 ± 5.6 vs. 62 ± 6.7 2021 USA Desroches et al. [ 10 ] 33,577,899 Urology Na RCT 66 vs. 66 69 60.1 (13.3) vs. 60 (12.5) / 60.1 (11.8) 35 vs. 35 / 38 29.2 (6.0) vs. 28.9 (5.6) / 31.2 (5.6) 2023 Lebanon Ayoub et al. [ 14 ] 37,704,868 Urology Yes Retro 65.1 ± 6.6 vs. 63.7 ± 7.3 2023 Italy Forte et al. [ 15 ] 37,440,928 Urology Yes Retro 2024 China Wei et al. [ 17 ] 38,381,369 Urology Yes RCT 53 (48; 64) vs. 57 (44; 63) 25.4 (22.7–27.7) vs. 24.3 (22.6–27.0) 2024 USA Chien et al. [ 16 ] 37,819,689 Urology No Retro 17.3 (16.4–22.3) vs. 16.5 (15.0–19.1) 2016 Japan Miyano et al. [ 23 ] 28,029,370 Abdominal No PNRCT 2021 USA Paull et al. [ 7 ] 32,333,365 Abdominal Yes Retro LAR Right hemicolectomy 40 vs. 54 24 vs. 32 55.2 ± 15.4 vs. 58.4 ± 9.7 55.5 ± 18.2 vs. 64.2 ± 13.2 55.0 vs. 42.6 70.8 vs. 46.9 27.9 ± 7.8 vs. 28.4 ± 6.5 29.7 ± 7.5 vs. 29.1 ± 7.3 2021 Austria Luketina et al. [ 11 ] 32,767,145 Abdominal No RCT Cholecystectomy Sigmoid resection 54.0 ± 12.9 vs. 55.2 ± 13.2 27.4 (24.6–31.0) vs. 27.8 (24.8–30.1) 2017 France Sroussi et al. [ 20 ] 28,403,972 Gynecology No RCT Tubal patency test Salpingectomy 33 (19–45) vs. 35 (25–58) 2020 USA Madueke-Laveaux et al. [ 18 ] 31,125,720 Gynecology No RCT Uterine myomas Endometriosis 33 vs.33 33 vs.33 40 ± 9 vs. 40 ± 7 39 ± 7 vs. 36 ± 8 27 ± 6 vs. 28 28 ± 7 vs. 27 2022 France Delecourt et al. [ 13 ] 35,569,811 Gynecology No RCT 25.3 (9.3) vs. 25.5 (5.5) 2022 Italy Buda et al. [ 12 ] 35,327,010 Gynecology Yes Retro 63 (52–73) vs. 65 (54–75) Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range) LAR low anterior resection, PNRCT prospective non randomized clinical trials, Retro Retrospective, RCT Randomized Clinical Trials, na no data available Table 2 Description of the laparoscopic outcomes Authors + PMID Specialty Robotic surgery Operative duration (min) AIRSEAL ® vs. Control Intra-abdominal pressure (mmHg) α AIRSEAL ® vs. Control CO 2 absorption rate (ml/kg/min) α AIRSEAL ® vs. Control End-tidal CO 2 (mmHg) α AIRSEAL ® vs. Control Volume of CO 2 (L) α AIRSEAL ® vs. Control Herati et al. [ 25 ] 20,888,033 Urology No 123 ± 43 vs. 146 ± 55 15 vs. 15 Na vs. na Na vs. na 111.7 ± 77.3 vs. 306.4 ± 218.5*** Horstmann et al. [ 2 ] 23,186,377 Urology Yes 175 (111–297) vs. 166 (113–276) 12 vs. 12 Na vs. na Na vs. na 1205 (400–2578) vs. 1044 (245–1674) George et al. [ 26 ] 25,725,807 Urology Yes 150 (45–325) vs. 170 (65–340) *** 10 vs. 12 Na vs. na Na vs. na Na vs. na Bucur et al. [ 1 ] 27,130,263 Urology No 151 (48) vs. 130 (35) 14.0 ± 1.3 vs. 14.7 ± 1.7 Na vs. na Na vs. na Na vs. na Annino et al. [ 22 ] 27,495,337 Urology Yes 140 vs. 157* 12 vs. 12 Na vs. na Na vs. na Na vs. na Covotta et al. [ 21 ] 28,452,822 Urology Yes 372 (77) vs. 344 (81) 12.4 ± 0.24 vs. 11.8 ± 0.18 4.2 ± 0.3 vs. 5.4 ± 0.3** 28.8 ± 0.5 vs. 31.3 ± 0.5** Na vs. na Shahait et al. [ 19 ] 30,740,014 Urology Yes 146 ± 35 vs. 167 ± 25** 15 vs. 15 Na vs. na Na vs. na Na vs. na Feng et al. [ 8 ] 32,632,561 Urology Yes Na vs. na 9.7 (1.8) / 11.4 (2.8) vs. 12.5 (3.2) Na vs. na Na vs. na Na vs. na Abaza et al. [ 9 ] 33,349,135 Urology Yes 159 vs. 153 6 vs. 6 Na vs. na 34.8 (15–46) vs. 34.2 (20–50) Na vs. na Desroches et al. [ 10 ] 33,577,899 Urology Yes Na vs. na 12 / 15 vs. 15 Na vs. na 33.9 (3.4)** / 35.0 (3.1) vs. 36.1 (4.1) Na vs. na Ayoub et al. [ 14 ] 37,704,868 Urology Yes 304 ± 45 vs. 317 ± 54 10 vs. 12 Na vs. na Na vs. na Na vs. na Forte et al. [ 15 ] 37,440,928 Urology na 109 vs. 121 12 vs. 12 Na vs. na Na vs. na Na vs. na Wei et al. [ 17 ] 38,381,369 Urology Yes 90 (90–128) vs. 100 (90–130) 12 vs. 15 Na vs. na 41 (36–44) vs. 45 (40–47)** Na vs. na Chien et al. [ 16 ] 37,819,689 Urology Mixed 237 (216–272) vs. 219 (191–245) 8 to 10 vs. 8 to 10 Na vs. na 39.1 (2.79) vs. 38.6 (3.01) Na vs. na Miyano et al. [ 23 ] 28,029,370 Abdominal no 72 ± 30 vs. 76 ± 32 7.9 ± 1.5 vs. 9 ± 1.2* Na vs. na 35.7 ± 3.7 vs. 38.5 ± 2.6* Na vs. na Paull et al. [ 7 ] 32,333,365 Abdominal Yes 185 ± 41 / 232 ± 75 vs. 192 ± 56 / 293 ± 92 Na vs. na Na vs. na Na vs. na Na vs. na Luketina et al. [ 11 ] 32,767,145 Abdominal No 71 (56–94) vs. 69 (52–93) 12 vs. 12 Na vs. na Na vs. na Na vs. na Sroussi et al. [ 20 ] 28,403,972 Gynecology No 26 (9–83) vs. 30 (10–85) 7 vs. 15 Na vs. na 36 (31–41) vs. 40 (33–46)*** Na vs. na Madueke-Laveaux et al. [ 18 ] 31,125,720 Gynecology Mixed 146 ± 79 / 141 ± 70 vs. 143 ± 73 / 129 ± 73 10 / 15 vs. 10 / 15 4 ± 1.1 vs. 4 ± 1.1 Na vs. na Na vs. na Delecourt et al. [ 13 ] 35,569,811 Gynecology No 147 (69) vs. 147 (77) 8 to 10 vs. 12 to 15 Na vs. na Na vs. na Na vs. na Buda et al. [ 12 ] 35,327,010 Gynecology No 113 (92–134) vs. 119 (84–154) 8.5 (7.5–9.5) vs. 11.3 (10.2–12.4) Na vs. na 33.7 (31.4–36.0) vs. 35.8 (32.3–39.3)*** 34.1 (29.9–38.3) vs. 47.9 (41.7–54.1)*** Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range), * p  < 0.05, ** p  < 0.01, and *** p  < 0.001 (p values from included publications) α: These data were not included in the PICO framework but were reported for completeness. na not available Description of the laparoscopic outcomes Herati et al. [ 25 ] 20,888,033 Horstmann et al. [ 2 ] 23,186,377 George et al. [ 26 ] 25,725,807 Bucur et al. [ 1 ] 27,130,263 Annino et al. [ 22 ] 27,495,337 Covotta et al. [ 21 ] 28,452,822 Shahait et al. [ 19 ] 30,740,014 Feng et al. [ 8 ] 32,632,561 9.7 (1.8) / 11.4 (2.8) vs. 12.5 (3.2) Abaza et al. [ 9 ] 33,349,135 Desroches et al. [ 10 ] 33,577,899 Ayoub et al. [ 14 ] 37,704,868 Forte et al. [ 15 ] 37,440,928 Wei et al. [ 17 ] 38,381,369 Chien et al. [ 16 ] 37,819,689 Miyano et al. [ 23 ] 28,029,370 Paull et al. [ 7 ] 32,333,365 185 ± 41 / 232 ± 75 vs. 192 ± 56 / 293 ± 92 Luketina et al. [ 11 ] 32,767,145 Sroussi et al. [ 20 ] 28,403,972 Madueke-Laveaux et al. [ 18 ] 31,125,720 146 ± 79 / 141 ± 70 vs. 143 ± 73 / 129 ± 73 Delecourt et al. [ 13 ] 35,569,811 Buda et al. [ 12 ] 35,327,010 Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) or median (interquartile range), * p  < 0.05, ** p  < 0.01, and *** p  < 0.001 (p values from included publications) α: These data were not included in the PICO framework but were reported for completeness. na not available Ten were conducted in the United States [ 1 , 7 – 10 , 16 , 18 , 19 , 24 , 25 ], while the remaining 11 originated from eight European centers [ 2 , 11 – 13 , 15 , 20 – 22 ], two Asian centers [ 17 , 23 ], and one Lebanon center [ 14 ]. Ten were randomized controlled trials (RCTs) [ 1 , 8 – 11 , 13 , 17 , 18 , 20 , 21 ], five were prospective non-RCTs [ 2 , 19 , 22 , 23 , 25 ], and six were retrospective cohort studies [ 7 , 12 , 14 – 16 , 24 ]. Only two studies were multicenter, which may account for the relatively small sample sizes (fewer than 100 patients) reported in 52% of the studies. Fourteen studies involved patients undergoing urologic procedures [ 1 , 2 , 8 – 10 , 14 – 17 , 19 , 21 , 22 , 24 , 25 ], 11 of which employed robotic-assistance [ 2 , 8 – 10 , 14 , 16 , 17 , 19 , 21 , 22 , 24 ]. The remaining seven studies included four gynecologic [ 12 , 13 , 18 , 20 ] and three abdominal surgery cohorts [ 7 , 11 , 23 ]. Most surgeries were performed for oncologic indications, except in six studies. Of the ten RCTs, six [ 8 , 11 , 13 , 17 , 18 , 21 ] were rated as high quality, while four were deemed of fair [ 1 , 10 , 20 ] or poor [ 9 ] quality (Appendix 2). The primary limitations included inadequate description of randomization procedures, or concerns about potential allocation or concealment bias. Of the 11 non-RCTs, two [ 19 , 24 ] were rated of fair quality, and 9 were judged of poor quality (Appendix 2). Common shortcomings involved incomplete reporting of baseline characteristics and study objectives, insufficient detail in statistical methods, and limited sample sizes. Overall, only six studies achieved a good quality rating, with the remainder deemed of fair ( n  = 5) or poor ( n  = 10) quality. Across all included studies, 2804 participants were enrolled, with 1,354 allocated to AIRSEAL ® groups and 1,450 to control groups. Baseline characteristics were generally balanced between groups, including proportions of female participants (excluding single-sex studies) ranging from 17.8% to 70.8% in AIRSEAL ® groups vs. 25.4% to 54.6% in controls. Age ranged from 8.8 to 66.3 years vs. 8.8 to 65.9 years respectively, and body mass index (BMI) ranges were 17.0–31.2 kg/m² and 16.5–29.3 kg/m² respectively. Reported pneumoperitoneum pressures varied between 5 and 15 mmHg in AIRSEAL ® groups and between 5 and 15 mmHg in control groups [ 2 , 8 – 25 ]. Table 3 Description of the perioperative blood loss, total complications, general pain and shoulder pain scores at 24-h, and hospital length of stay Authors PMID Specialty Blood loss (ml) AIRSEAL ® vs. Control Total complications (%) AIRSEAL ® vs. Control General pain scores at 24-h (NRS) AIRSEAL ® vs. Control Shoulder pain scores at 24-h (NRS) AIRSEAL ® vs. Control Hospital length of stay (days) AIRSEAL ® vs. Control Herati et al. [ 25 ] 20,888,033 Urology 304 (100; 800) vs. 319 (50; 1700) 11.5 vs. 8 Na vs. na Na vs. na 2.6 ± 1.1 vs. 2.2 ± 1.0 Horstmann et al. [ 2 ] 23,186,377 Urology 290 (100; 1200) vs. 215 (100; 450) 26.3 vs. 5.9* Na vs. na Na vs. na Na vs. na George et al. [ 26 ] 25,725,807 Urology 257 (0; 2000) vs. 224 (0; 1500) 0.5 vs. 0.8 Na vs. na Na vs. na Na vs. na Bucur et al. [ 1 ] 27,130,263 Urology 155 ± 168 vs. 75 ± 91* 17.9 vs. 35.7 3.7 ± 2.2 vs. 3.8 ± 2.1 1.6 ± 2.1 vs. 1.9 ± 2.6 2.2 ± 1.2 vs. 2.5 ± 1.1 Annino et al. [ 22 ] 27,495,337 Urology Na vs. na 10.4 vs. 16.4 Na vs. na Na vs. na Na vs. na Covotta et al. [ 21 ] 28,452,822 Urology 448 ± 302 vs. 485 ± 315 Na vs. na Na vs. na Na vs. na Na vs. na Shahait et al. [ 19 ] 30,740,014 Urology 133 ± 66 vs. 144 ± 58 5 vs. 4 2.2 vs. 3.4 Na vs. na 1 ± 1 vs. 1 ± 0 Feng et al. [ 8 ] 32,632,561 Urology Na vs. na Na vs. na Na vs. na Na vs. na 1.3 (0.7) / 1.1 (0.3) vs. 1.2 (0.4) Abaza et al. [ 9 ] 33,349,135 Urology 146.5 vs. 126.5* Na vs. na Na vs. na Na vs. na 0.4 vs. 0.3 Desroches et al. [ 10 ] 33,577,899 Urology Na vs. na Na vs. na Na vs. na Na vs. na Na vs. na Ayoub et al. [ 14 ] 37,704,868 Urology 270 ± 156 vs. 235.5 ± 120 13.6 vs. 13.9 Na vs. na Na vs. na 1.5 ± 0.1 vs. 2.0 ± 0.1*** Forte et al. [ 15 ] 37,440,928 Urology Na vs. na 0 vs. 7.7 Na vs. na Na vs. na Na vs. na Wei et al. [ 17 ] 38,381,369 Urology 50 (20–50) vs. 50 (20–50) Na va na Na- vs. na Na vs. na 5 (4 6) vs. 5 (4; 6) Chien et al. [ 16 ] 37,819,689 Urology 22.5 (2.5–47.5) vs. 25.0 (5.0–25.0) 7.1 vs. 16.7 Na vs. na Na vs. na 1 (1–2) vs. 1 (1–2) Miyano et al. [ 23 ] 28,029,370 Abdominal 4 ± 3 vs. 4 ± 2 5.6 vs. 0 Na vs. na Na vs. na 4.3 ± 2.3 vs. 3.8 ± 1.1 Paull et al. [ 7 ] 32,333,365 Abdominal 135 ± 183.1 / 150 ± 173 vs. 156 ± 209 / 209 ± 189 12.5 / 8.3 vs. 9.3 / 6.3 Na vs. na Na vs. na 3.8 ± 1.5 / 4.3 ± 3.1 vs. 4.9 ± 2.4 / 4.6 ± 3.7 Luketina et al. [ 11 ] 32,767,145 Abdominal Na vs. na 6.2 vs. 6.3 Na vs. na 2.7 (0–8) vs. 1.5 (0–6)*** 3.50 (3–4.5) vs. 4 (3–5) Sroussi et al. [ 20 ] 28,403,972 Gynecology Na vs. na Na vs. na Na vs. na 0.5 (0; 6) vs. 1.5 (0; 6)** Na vs. na Madueke-Laveaux et al. [ 18 ] 31,125,720 Gynecology 178 ± 169 / 113 ± 130 vs. 235 ± 365 / 186 ± 271 3.0 / 3.0 vs. 9.1 / 0 Na vs. na 0 / 0 vs. 0 / 0 Na vs. na Delecourt et al. [ 13 ] 35,569,811 Gynecology 100 (150) vs. 100 (163) 2.5 vs. 0 Na vs. na 1.27 ± 2,7 vs. 0.48 ± 1.1 4 (1) vs. 4 (1) Buda et al. [ 12 ] 35,327,010 Gynecology 122.0 (77.6–166.4) vs. 121.0 (79.6–162.4) 0 vs. 2.9 0.2 (0–0.8) vs. 1.1 (0.2-2.0)*** Na vs. na 2.0 (1.4–2.6) vs. 2.2 (1.4–3.0) Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) and median (interquartile range) na not available, NRS numeric rating scale * p  < 0.05, ** p  < 0.01, and *** p  < 0.001 (p values from included publications) Description of the perioperative blood loss, total complications, general pain and shoulder pain scores at 24-h, and hospital length of stay Herati et al. [ 25 ] 20,888,033 Horstmann et al. [ 2 ] 23,186,377 George et al. [ 26 ] 25,725,807 Bucur et al. [ 1 ] 27,130,263 Annino et al. [ 22 ] 27,495,337 Covotta et al. [ 21 ] 28,452,822 Shahait et al. [ 19 ] 30,740,014 Feng et al. [ 8 ] 32,632,561 Abaza et al. [ 9 ] 33,349,135 Desroches et al. [ 10 ] 33,577,899 Ayoub et al. [ 14 ] 37,704,868 Forte et al. [ 15 ] 37,440,928 Wei et al. [ 17 ] 38,381,369 Chien et al. [ 16 ] 37,819,689 Miyano et al. [ 23 ] 28,029,370 Paull et al. [ 7 ] 32,333,365 Luketina et al. [ 11 ] 32,767,145 Sroussi et al. [ 20 ] 28,403,972 Madueke-Laveaux et al. [ 18 ] 31,125,720 Delecourt et al. [ 13 ] 35,569,811 Buda et al. [ 12 ] 35,327,010 Madueke-Laveaux et al.: AIRSEAL ® group 10mmHg/15mmHg and control group 10mmHg/15mmHg Desroches et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Feng et al.: AIRSEAL ® group 12mmHg/15mmHg and control group 15mmHg Paull et al.: 4 groups Low anterior resection with traditional system versus AIRSEAL ® and right hemicolectomies with traditional system versus AIRSEAL ® Results are expressed by mean ± standard deviation, median (min; max) and median (interquartile range) na not available, NRS numeric rating scale * p  < 0.05, ** p  < 0.01, and *** p  < 0.001 (p values from included publications) Postoperative pain, including general or shoulder pain, was evaluated in 10 studies [ 1 , 8 , 10 – 13 , 17 – 20 ]. There was heterogeneity across studies in terms of time points to assess pain (2 h postoperatively, 6 h, 24 h, etc.). We chose to report here pain measurements at 24 h, which was the time point the most frequently described and deemed of greater relevance, while other outcomes are available in Appendix 3. Of these, five reported a statistically significant reduction in shoulder pain [ 8 , 10 – 12 , 20 ] and three in general pain [ 12 , 17 , 19 ] after surgery in the AIRSEAL ® group compared to standard insufflation. The remaining studies found no significant differences in postoperative pain scores between groups. Regarding analgesic consumption, of the six studies that assessed the use of analgesic [ 1 , 8 , 9 , 12 , 14 , 20 ], three [ 12 , 14 , 20 ] reported a significant reduction at 24 h postoperatively in patients treated with AIRSEAL ® compared to the control group while in the three others [ 1 , 8 , 9 ] no significant difference was observed. Fourteen studies [ 1 , 2 , 7 , 10 , 11 , 13 , 14 , 16 , 18 , 19 , 22 – 25 ] reported the overall complication rates within 30 days post-surgery. In the majority of these, complication rates were comparable between the AIRSEAL ® and the control groups [ 1 , 7 , 11 , 13 , 14 , 16 , 18 , 19 , 22 – 25 ]. Two studies reported discrepant findings with one [ 2 ] where a higher incidence of total complications was found in the AIRSEAL ® group, specifically subcutaneous emphysema ( p < 0.05), while in another study [ 10 ] a lower incidence of subcutaneous emphysema was shown in the AIRSEAL group ( p < 0.05). The rate of severe complications (Clavien–Dindo grade ≥ 2 ), which was reported in four studies [ 2 , 10 , 11 , 13 ], did not differ between groups. Intraoperative blood loss was measured in 15 studies [ 1 , 2 , 7 , 9 , 10 , 12 – 14 , 16 – 19 , 23 – 25 ], showing ranges from 3.6 to 448 ml in the AIRSEAL ® groups vs. 3.5 to 485 ml in control groups. In 11 of these [ 2 , 10 , 12 , 13 , 16 – 19 , 23 – 25 ], no difference was found between groups. Three studies [ 1 , 9 , 14 ] reported a statistically significant increase in blood loss in the AIRSEAL ® group whereas in one study [ 7 ], authors showed a decrease in blood loss in the AIRSEAL ® group. Postoperative blood transfusion rates were similar across groups in five studies [ 11 , 14 , 15 , 22 , 24 ]. Conversion to laparotomy was a rarely reported outcome (five studies [ 11 , 13 , 15 , 18 , 24 ]) and appeared to be of exceptional occurrence with no difference between groups. None of the studies included outcomes on 30-day hospital readmission rates. Operative times varied between 26 and 372 min in the AIRSEAL ® groups compared to 30 to 344 min in the control groups. Five studies [ 7 , 14 , 19 , 22 , 24 ] reported shorter operative durations with AIRSEAL ® compared to control groups. Eleven studies found no difference in operative duration between groups [ 8 , 9 , 11 – 13 , 16 , 17 , 20 , 21 , 23 , 24 ], and two studies did not provide statistical analysis on this variable [ 15 , 18 ]. Postoperative room stay was reported in three studies [ 8 , 18 , 21 ], with durations ranging from 127 to 260 min in the AIRSEAL ® group and 147 to 285 min in control groups. Hospital length of stay was assessed in 13 studies [ 1 , 7 – 9 , 11 – 14 , 16 , 17 , 19 , 23 , 25 ], with median stays ranging from 0.4 to 5 days for AIRSEAL ® patients and 0.3 to 5 days for controls. No significant differences were found between groups for either postoperative room stay or overall hospitalization time. None of the included studies reported data on the costs associated with surgical management.

Conclusion

Available evidence confirms that the AIRSEAL ® device is a feasible option for use in laparoscopic surgery. Current evidence does not demonstrate consistent clinical superiority of valve-less trocar insufflation systems over conventional insufflators, although several perioperative and organizational benefits have been reported. Given the heterogeneity and overall quality of the available evidence, further high-quality studies are warranted. The present systematic review provides a synthesis of the current literature on the patient outcomes and organizational impact of a valve-less trocar insufflation system and may constitute a valuable basis for future evidence appraisal and the development of clinical practice guidelines. Future reviews focusing on surgeon-reported outcome measures could be considered to complement the present findings.

Discussion

To date, most data on the safety and feasibility of the AIRSEAL ® system are derived from studies conducted in urologic surgery, but also from gynecologic and digestive surgery. Our previous review reported no significant differences between groups in terms of overall complication rates, post-anesthesia care unit stay, or total length of hospitalization, and findings related to postoperative pain were inconsistent [ 3 ]. The objective of this work was to provide an updated and critical assessment of the existing literature on the use of the AIRSEAL ® device in laparoscopic and robotic surgeries, based on patient and organizational outcomes. This evaluation was considered necessary given the increasing adoption of the AIRSEAL ® system in surgical practices, despite its relatively high per-procedure cost. Moreover, the lack of a formal health technology assessment highlights the need for evidence-based insights to support institutional decision-making. With regard to blood loss, most studies did not find significant differences between groups. Three studies reported increase blood loss in the AIRSEAL ® group [ 1 , 9 , 14 ]; however, given the overall low volumes involved, the clinical relevance of such differences remains questionable, transfusion was required in only one study [ 14 ] without difference between groups. Regarding conversions to laparotomy, few studies reported this outcome, and when it was mentioned, the underlying causes, such as difficulties to obtain a correct exposure or other intraoperative challenges, were rarely detailed. Finally, operative times were not prolonged in the studies reviewed; in fact, five studies reported a reduction in surgical duration [ 7 , 14 , 19 , 22 , 24 ]. We may speculate that the improvement of visualization, reduced need for lens cleaning, and greater pneumoperitoneum stability with the use of the AIRSEAL ® device. Nevertheless, although a reduced operative time was observed in five of the studies with the largest sample sizes, the data remain heterogeneous, and most studies do not demonstrate any significant difference in operative duration. Regarding overall postoperative complications, no significant differences was observed between groups using the AIRSEAL ® device and those using conventional insufflation. However, findings related to subcutaneous emphysema remain inconsistent: while one study reported an increased incidence in the AIRSEAL ® group [ 2 ], another found a decreased occurrence [ 10 ]. In contrast, few studies have specifically examined the rate of severe complications, defined as Clavien-Dindo grade ≥ 2. No significant differences in the occurrence of these severe complications between the AIRSEAL ® and conventional insufflation groups were found. Postoperative pain was considered one of the most clinically relevant outcomes to evaluate the potential benefit of AIRSEAL ® device. However, findings on postoperative pain were not consistent: about half of the studies found no significant difference, while the other half reported a reduction in shoulder pain [ 8 , 10 – 12 , 20 ], which is a common complaint following laparoscopic surgery but its etiology is not well understood. Similarly, postoperative analgesic consumption was reported as either comparable between groups in three out of six studies [ 1 , 8 , 9 ] or reduced in the others [ 12 , 14 , 20 ]. However, despite a trend toward reduced pain and analgesic consumption, the length of hospital stay was similar between groups in all 13 studies that assessed this outcome. Intraoperative data reported in the studies include parameters related to pneumoperitoneum, ventilatory variables, blood loss, and conversion to laparotomy. Elevated CO₂ absorption has been associated with several factors, including higher insufflation pressures, extended duration of pneumoperitoneum, gas leakage around trocars, and the presence of subcutaneous emphysema [ 25 ]. Increased CO₂ uptake during surgery can lead to clinically significant consequences, such as respiratory acidosis and, in rare cases, gas embolism [ 26 ]. Among the selected studies, only three have directly assessed total CO₂ consumption, with two studies reporting a lower volume use in the AIRSEAL ® group. Additionally, six studies reported reduced end-tidal CO₂ (EtCO₂) levels, although only one study simultaneously evaluated both CO 2 consumption and EtCO 2 , showing reductions in both parameters. Based on findings from this single study, we further hypothesize an improvement in physiologic tolerance to laparoscopy. However, very limited data are available on these parameters, and the existing evidence is highly heterogeneous. Therefore, larger-scale studies will be necessary to properly assess these outcomes and to confirm, or refute, any improvement in physiological tolerance associated with the AIRSEAL ® system. Variations in intra-abdominal pressure and prolonged Trendelenburg positioning may further increase the amount of CO₂ that needs to be eliminated by the body over the course of the procedure. However, the Trendelenburg position is commonly used in urologic and gynecologic surgeries, which represent the majority of the studies included in this review. This could partly explain why no significant differences, or only minimal differences in a few studies, were observed. Ultimately, an important factor in the decision to change clinical practice, particularly the adoption of a new device, is the presence of economic evaluations. Indeed, the cost of an expensive device could be in theory offset by substantial savings due to reduction of resource use and/or substantial clinical benefit. Despite the substantial cost of the AIRSEAL ® device, it is noteworthy that no study has yet conducted such an evaluation. Although this systematic review was conducted in accordance with PRISMA guidelines, it has several limitations. The primary one concerns the overall quality of the studies included: of the 21 studies analyzed, only 10 were RCTs, and among these, only six were of high quality. Moreover, the sample sizes of the included studies are limited, as only two were multicenter RCTs. The second limitation is that all types of laparoscopic surgeries were included, which may have introduced heterogeneity in the outcomes such as operative time, blood loss, and others. Another limitation is that no formal assessment of the certainty of evidence (e.g., GRADE) was performed, as our main objective was to provide a synthesis of the available literature based on patient outcomes and organizational impact rather than to formulate clinical practice recommendations. Nevertheless, this work may provide an evidence base for future guideline development using formal evidence appraisal methods. Finally, the outcomes included in this review were predefined according to the PICO framework and focused on patient outcomes and organizational endpoints. Consequently, surgeon-centered outcomes, such as perceived operative comfort, pneumoperitoneum stability, ease of specimen retrieval, or overall user experience, were not evaluated. These correspond to practical advantages of the AIRSEAL ® device, including reduced fogging, decreased need for repeated lens cleaning, and a smoother overall operative course. Such outcomes represent important determinants of the perceived value of valve-less insufflation systems and should be assessed in future reviews using validated surgeon-reported outcome measures. Nonetheless, our review offers a broad overview of the current literature, regardless of the specific surgical field. Additionally, we observed that many studies either lacked clinically relevant outcomes or reported them inconsistently often due to variations in outcome definitions or measurement time points. The absence of significant differences in most of clinical endpoints should not be interpreted as evidence of equivalence across all dimensions of performance, and that workflow-related advantages of valveless systems may not be fully captured by the outcomes analyzed in our review.

Introduction

Minimally invasive surgery has seen remarkable progress over recent decades, with laparoscopic and robotic techniques now forming the cornerstone of many surgical interventions. A critical component of these procedures is the creation and maintenance of a stable pneumoperitoneum, typically achieved through carbon dioxide (CO₂) insufflation. Traditionally, this has relied on standard insufflation systems equipped with one-way valve trocars, which, despite their widespread use, present several limitations. These include pressure loss during instrument exchanges, inadequate smoke evacuation, moisture accumulation on camera lenses, and fluctuations in intra-abdominal pressure that may compromise surgical exposure and patient safety [ 1 ]. To overcome these limitations, a new generation of insufflation devices has emerged, characterized by a valveless, barrier-free design [ 2 ]. Among these, the AIRSEAL ® device (SurgiQuest, Milford, CT) stands out due to its unique ability to provide continuous CO₂ insufflation, active gas recirculation, and real-time smoke evacuation while maintaining constant intra-abdominal pressure, even in the presence of high suction or significant leaks [ 1 ]. This technological innovation is designed to minimize complications related to pressure instability, such as hypercapnia, acidosis, shoulder pain, or CO 2 pressure disruption, while optimizing surgical performance and reducing operative time. Given the increasing adoption of this medical technology across operating rooms worldwide, a critical evaluation of its clinical benefits compared to conventional insufflators is warranted. In 2020, we published a systematic review that reported inconclusive findings regarding the clinical and organizational impact of this technology [ 3 ]. Here, we presented an update of our systematic review (SR) to determine the current state of art regarding the potential advantages of the AIRSEAL ® device over standard CO₂ insufflation device in terms of intraoperative stability, surgical efficiency, and patient outcomes.

Supplementary Material

Supplementary Material 1: Appendix 1: Literature search strategies (22 May 2024). Appendix 2: Quality assessment of included studies. Appendix 3: Table S1: Description of general pain scores at different time point and Table S2: Description of shoulder pain scores at different time point. Supplementary Material 1: Appendix 1: Literature search strategies (22 May 2024). Appendix 2: Quality assessment of included studies. Appendix 3: Table S1: Description of general pain scores at different time point and Table S2: Description of shoulder pain scores at different time point. Supplementary Material 2. Supplementary Material 2.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc-nxml ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

chemicals 3
carbon dioxide carbon dioxide carbon dioxide

Source provenance

europepmc
last seen: 2026-11-15T09:34:25.365398+00:00
scilite
last seen: 2026-11-08T10:40:02.467495+00:00
unpaywall
last seen: 2026-11-09T06:31:04.326590+00:00
License: CC-BY-NC-ND-4.0